Home Tools
Log in
Cart

Mdm2

Mouse double minute 2 homolog (MDM2) also known as E3 ubiquitin-protein ligase Mdm2 is a protein that in humans is encoded by the MDM2 gene. Mdm2 is an important negative regulator of the p53 tumor suppressor. Mdm2 protein functions both as an E3 ubiquitin ligase that recognizes the N-terminal trans-activation domain (TAD) of the p53 tumor suppressor and as an inhibitor of p53 transcriptional activation.
Cat. No. Product name CAS No. Purity Chemical Structure
T16771 RO-5963 1416663-77-8 98%
RO-5963 is a dual inhibitor of p53-MDM2 and p53-MDMX (IC50s: ~17 nM and ~24 nM, respectively).
TN4107 Ganoderic acid X 86377-53-9 98%
Ganoderic acid X is a potential Mdm2 inhibitor(K(i) = 16nM). It is a potential anticancer drug, inhibits topoisomerases and induces apoptosis of cancer cells.
T14203 AM-8735 1429386-01-5 98%
AM-8735 is an inhibitor of MDM2 ( IC50: 25 nM).
T6585 SAR405838 1303607-60-4 98%
MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.
T67698 WAY-300374 350678-63-6 98%
WAY-300374 inhibits the p53-MDM2 protein-protein interaction.
T11931 MA242 1049704-18-8 98%
MA242 is a nuclear factor of activated T cells 1 (NFAT1) for Pancreatic Cancer Therapy and dual inhibitor of murine double minute 2 (MDM2).
T12040 Milademetan 1398568-47-2 98%
Milademetan is a specific and oral inhibitor of MDM2.
TN1805 Isosilybin B 142796-22-3 98%
Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway, it has anti-prostate cancer (PCA) activit...
T12031 MI-1061 1410737-34-6 98%
MI-1061 is a orally bioavailable inhibitor of MDM2 (MDM2-p53 interaction) (IC50=4.4 nM).
TQ0127 Navtemadlin 1352066-68-2 98%
AMG 232 is a potent, selective and orally available inhibitor of p53-MDM2 interaction (IC50: 0.6 nM). It binds to MDM2 with a Kd of 0.045 nM.
T12027 MG-277 T12027 98%
MG-277 is a molecular glue compound transformed from PROTAC degradation agent, MG-277 potently inhibits tumor cell growth in a p53-independent manner.
TN4341 IVHD-valtrate 28325-56-6 98%
VHD-valtrate has anticancer effects against human ovarian cancer cells in vitro and in vivo, it is a potential therapeutic agent for ovarian cancer, providing a ...
T28509 RDR03871 286008-51-3 98%
RDR03871 is an MDM2 inhibitor.
T9698 UC2288 1394011-91-6 98%
UC2288 is a relatively selective p21 attenuator which is synthesized based Sorafenib. UC2288 attenuates p21 protein levels with minimal effect on p21 protein sta...
T11980 MD-224 2136247-12-4 100%
MD-224 is a highly potent and efficacious MDM2 degrader based on the proteolysistargeting chimera (PROTAC) concept,and as a new class of anticancer agent.
T2243 Serdemetan 881202-45-5 98%
Serdemetan is an orally bioavailable HDM2 antagonist with potential antineoplastic activity.
T16523L PhiKan 083 880813-36-5 98.2%
PhiKan 083 is a carbazole derivative
T2179 Triptolide 38748-32-2 98.52%
Triptolide is a diterpenes trioxide, immunosuppressive agent extracted from the Chinese herb Tripterygium wilfordii.
T14303 Alrizomadlin 1818393-16-6 98.69%
Alrizomadlin is an orally active inhibitor of MDM2 with IC50 of 3.8 nM and Ki of 1 nM, respectively[1]. Alrizomadlin blocks the interaction of MDM2 and p53 and i...
T6614 Nutlin-3b 675576-97-3 98.83%
Nutlin-3b is a p53/MDM2 antagonist or inhibitor (IC50: 13.6 μM), 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nu...
RO-5963
T16771
RO-5963 is a dual inhibitor of p53-MDM2 and p53-MDMX (IC50s: ~17 nM and ~24 nM, respectively).
Ganoderic acid X
TN4107
Ganoderic acid X is a potential Mdm2 inhibitor(K(i) = 16nM). It is a potential anticancer drug, inhibits topoisomerases and induces apoptosis of cancer cells.
AM-8735
T14203
AM-8735 is an inhibitor of MDM2 ( IC50: 25 nM).
SAR405838
T6585
MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.
WAY-300374
T67698
WAY-300374 inhibits the p53-MDM2 protein-protein interaction.
MA242
T11931
MA242 is a nuclear factor of activated T cells 1 (NFAT1) for Pancreatic Cancer Therapy and dual inhibitor of murine double minute 2 (MDM2).
Milademetan
T12040
Milademetan is a specific and oral inhibitor of MDM2.
Isosilybin B
TN1805
Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway, it has anti-prostate cancer (PCA) activit...
MI-1061
T12031
MI-1061 is a orally bioavailable inhibitor of MDM2 (MDM2-p53 interaction) (IC50=4.4 nM).
Navtemadlin
TQ0127
AMG 232 is a potent, selective and orally available inhibitor of p53-MDM2 interaction (IC50: 0.6 nM). It binds to MDM2 with a Kd of 0.045 nM.
MG-277
T12027
MG-277 is a molecular glue compound transformed from PROTAC degradation agent, MG-277 potently inhibits tumor cell growth in a p53-independent manner.
IVHD-valtrate
TN4341
VHD-valtrate has anticancer effects against human ovarian cancer cells in vitro and in vivo, it is a potential therapeutic agent for ovarian cancer, providing a ...
RDR03871
T28509
RDR03871 is an MDM2 inhibitor.
UC2288
T9698
UC2288 is a relatively selective p21 attenuator which is synthesized based Sorafenib. UC2288 attenuates p21 protein levels with minimal effect on p21 protein sta...
MD-224
T11980
MD-224 is a highly potent and efficacious MDM2 degrader based on the proteolysistargeting chimera (PROTAC) concept,and as a new class of anticancer agent.
Serdemetan
T2243
Serdemetan is an orally bioavailable HDM2 antagonist with potential antineoplastic activity.
PhiKan 083
T16523L
PhiKan 083 is a carbazole derivative
Triptolide
T2179
Triptolide is a diterpenes trioxide, immunosuppressive agent extracted from the Chinese herb Tripterygium wilfordii.
Alrizomadlin
T14303
Alrizomadlin is an orally active inhibitor of MDM2 with IC50 of 3.8 nM and Ki of 1 nM, respectively[1]. Alrizomadlin blocks the interaction of MDM2 and p53 and i...
Nutlin-3b
T6614
Nutlin-3b is a p53/MDM2 antagonist or inhibitor (IC50: 13.6 μM), 150-fold less potent (+)-enantiomer of Nutlin-3 as in comparison with opposite (-)-enantiomer Nu...
1 2